rabeprazole has been researched along with Cholera Infantum in 12 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Proton pump inhibitors (PPIs) are frequently coadministered with calcineurin inhibitors (CNIs) such as tacrolimus (TAC) and cyclosporin A (CSA), to treat or prevent upper gastrointestinal complications in Japanese patients with connective tissue diseases (CTDs)." | 7.80 | The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases. ( Hanafusa, T; Hata, K; Hirano-Kuwata, S; Isoda, K; Kotani, T; Makino, S; Shoda, T; Takeuchi, T; Yoshida, S, 2014) |
| "Rabeprazole (Aciphex, Alfence, Pariet) is a proton pump inhibitor (PPI) used for the treatment of adults with conditions requiring a reduction of gastric acid secretion such as erosive or ulcerative gastro-oesophageal reflux disease (GORD), non-erosive reflux disease (NERD), duodenal and gastric ulcers, and pathological hypersecretory conditions including Zollinger-Ellison syndrome (ZES)." | 4.85 | Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. ( Baldwin, CM; Keam, SJ, 2009) |
| "Proton pump inhibitors (PPIs) are frequently coadministered with calcineurin inhibitors (CNIs) such as tacrolimus (TAC) and cyclosporin A (CSA), to treat or prevent upper gastrointestinal complications in Japanese patients with connective tissue diseases (CTDs)." | 3.80 | The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases. ( Hanafusa, T; Hata, K; Hirano-Kuwata, S; Isoda, K; Kotani, T; Makino, S; Shoda, T; Takeuchi, T; Yoshida, S, 2014) |
| "Rabeprazole is a proton pump inhibitor that can be used in the treatment of acid-peptic-related disorders (gastroesophageal reflux disease [GERD], duodenal ulcer, gastric ulcer, gastric acid hypersecretory syndromes) and Helicobacter pylori." | 2.45 | Rabeprazole: a pharmacologic and clinical review for acid-related disorders. ( Dadabhai, A; Friedenberg, FK, 2009) |
| "Gastric acid is pathogenic in many gastrointestinal disorders, such as gastroesophageal reflux disease and peptic ulcer disease." | 2.43 | Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. ( Robinson, M, 2005) |
| "Rabeprazole is likely to be a valuable new addition to its class in treating patients with acid-related gastrointestinal diseases given its efficacy in acid suppression, high healing rates, rapid symptom relief, and convenient dosing." | 2.40 | Review article: rabeprazole's profile in patients with gastrointestinal diseases. ( Barth, J; Humphries, TJ, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Torres, I | 1 |
| De la Mora-De la Mora, I | 1 |
| Hernández-Alcántara, G | 1 |
| Molina-Ortiz, D | 1 |
| Caballero-Salazar, S | 1 |
| Olivos-García, A | 1 |
| Nava, G | 1 |
| López-Velázquez, G | 1 |
| Enríquez-Flores, S | 1 |
| Isoda, K | 1 |
| Takeuchi, T | 1 |
| Kotani, T | 1 |
| Hirano-Kuwata, S | 1 |
| Shoda, T | 1 |
| Hata, K | 1 |
| Yoshida, S | 1 |
| Makino, S | 1 |
| Hanafusa, T | 1 |
| Suzuki, S | 1 |
| Gotoda, T | 1 |
| Kusano, C | 1 |
| Iwatsuka, K | 1 |
| Moriyama, M | 1 |
| Dadabhai, A | 1 |
| Friedenberg, FK | 1 |
| Baldwin, CM | 1 |
| Keam, SJ | 1 |
| Laheij, RJ | 2 |
| Van Rossum, LG | 2 |
| Jansen, JB | 2 |
| Verheugt, FW | 2 |
| Vlemmix, F | 1 |
| Hata, M | 1 |
| Shiono, M | 1 |
| Sekino, H | 1 |
| Furukawa, H | 1 |
| Sezai, A | 1 |
| Iida, M | 1 |
| Yoshitake, I | 1 |
| Hattori, T | 1 |
| Wakui, S | 1 |
| Soeda, M | 1 |
| Taoka, M | 1 |
| Negishi, N | 1 |
| Sezai, Y | 1 |
| Robinson, M | 1 |
| Lebedenko, OB | 1 |
| Hussain, A | 1 |
| Al-Saeed, AH | 1 |
| Habib, SS | 1 |
| Humphries, TJ | 1 |
| Barth, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori[NCT05957432] | Phase 2 | 90 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for rabeprazole and Cholera Infantum
| Article | Year |
|---|---|
Rabeprazole: a pharmacologic and clinical review for acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Gastric Acid; | 2009 |
Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Gastric Acid; Gastroesophagea | 2009 |
Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Gastroesop | 2005 |
Review article: rabeprazole's profile in patients with gastrointestinal diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastr | 1999 |
3 trials available for rabeprazole and Cholera Infantum
| Article | Year |
|---|---|
Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
Health-related quality of life in patients with cardiovascular disease--the effect of upper gastrointestinal symptom treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cardiovascular Diseases; | 2004 |
Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cardiac Surgical Procedu | 2005 |
5 other studies available for rabeprazole and Cholera Infantum
| Article | Year |
|---|---|
First characterization of a microsporidial triosephosphate isomerase and the biochemical mechanisms of its inactivation to propose a new druggable target.
Topics: Albendazole; Amino Acid Sequence; Encephalitozoon; Fungal Proteins; Gastrointestinal Diseases; Gene | 2018 |
The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases.
Topics: Calcineurin Inhibitors; Connective Tissue Diseases; Cyclosporine; Cytochrome P-450 CYP2C19; Drug Int | 2014 |
The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Monitoring; Drug Therap | 2016 |
[Rabeprazole in the treatment of acid-dependent diseases in children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Child; Endoscopy, Gastrointe | 2006 |
Effect of single oral dose of sodium rabeprazole on the intragastric pH & volume in patients undergoing elective surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Elective Su | 2008 |